Cookies help us deliver our services. By using our services, you agree to our use of cookies.
Learn more
OK
Skip to main content (Press Enter).
Sign In
Skip auxiliary navigation (Press Enter).
Contact Us
Skip main navigation (Press Enter).
Toggle navigation
Search Options
About
What is the AMS
AMS International Scientific Committee
AMS Educational Executive Committee
AMS Ambassadors
Certification & Accreditation
Upcoming Events
Videos & Webinars
International Events
Become a Speaker
Videos On Demand
Education 365
Features
AMS Features
Blogs
Industry
Industry Partners
Become a Sponsor
Features
Blogs
Blog Viewer
Blogs
Cost per responder analysis of guselkumab versus targeted therapies in the treatment of moderate to severe plaque psoriasis in Germany
By
- AMS
posted
Jul 27, 2020 07:57 AM
0
Recommend
.
0 comments
0 views
Related Content
Cost per responder for guselkumab versus secukinumab in the United States based on a head-to-head trial of moderate to severe plaque psoriasis
- AMS
Added Jun 04, 2020
Blog Entry
New evidence-based resources to guide treatment of plaque psoriasis
- AMS
Added Sep 08, 2021
Blog Entry
Cost per PASI-75 responder of calcipotriol plus betamethasone dipropionate cutaneous foam versus nonbiologic systemic therapies for the treatment of plaque psoriasis in seven European countries
- AMS
Added Mar 06, 2020
Blog Entry
Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study
- AMS
Added Aug 05, 2021
Blog Entry
An economic evaluation of risankizumab versus other biologic treatments of moderate to severe plaque psoriasis in Japan
- AMS
Added Apr 17, 2020
Blog Entry
Permalink
© 2022 AMS, Aesthetic Multispecialty Society. All Rights Reserved.
Powered by Higher Logic